Clinical Trials Logo

Clinical Trial Summary

The purpose of this open, multicenter phase II trial is to confirm the tolerance and evaluate the efficacy of the SclerFIX product, an allograft of umbilical cord lining membrane, in reinforcement of scleral thinning in patients who underwent eye tumor exeresis.


Clinical Trial Description

As scleral graft is forbidden in France, it cannot be used to reinforce the sclera. This study investigational product, SclerFIX, was developed to substitute scleral grafts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05302609
Study type Interventional
Source TBF Genie Tissulaire
Contact Laurence BARNOUIN, MD
Phone 4 72 68 69 09
Email laurence.barnouin@tbf-lab.com
Status Recruiting
Phase Phase 2
Start date July 4, 2022
Completion date July 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT00801073 - Comparison Amongst Scleral, Corneal and Amniotic Membrane Grafts to Restore Scleral Thinning Phase 2/Phase 3